Medicine
Pharmacokinetic Changes in Hepatic Impairment and Dose Adjustment
Quick fact
In cirrhosis, the liver's drug-metabolizing capacity can be reduced by up to 75%, leading to higher drug levels and increased risk of toxicity. For example, the half-life of morphine can double, increasing sedation and respiratory depression risk.
Why this is interesting
Many medications are cleared by the liver, so what happens when the liver is damaged? The answer is that drug effects can become dangerously strong, but doctors can predict and prevent this.
Read the full explanation
Understanding Pharmacokinetic Changes in Hepatic Impairment and Dose Adjustment
Imagine the liver as a busy recycling plant that breaks down many drugs into harmless waste. When the liver is scarred (cirrhosis), the plant's machinery is damaged: enzymes (the workers) are fewer and slower, and the blood flow through the plant is reduced. This means drugs pass through the liver without being fully processed, so more of the active drug reaches the rest of the body. Also, the liver makes albumin, a protein that binds many drugs in the blood. In liver disease, albumin levels drop, leaving less drug bound and more free, active drug. Thus, even normal doses can cause excessive effects. This is why doctors must lower doses or extend the time between doses.
A deeper explanation
The mechanism of altered pharmacokinetics in hepatic impairment is multifaceted. First, reduced hepatocellular function lowers the expression and activity of cytochrome P450 enzymes, especially CYP3A4, CYP2C19, and CYP2D6, slowing the metabolic clearance of many drugs. Second, portal hypertension and shunting reduce hepatic blood flow, decreasing the clearance of high-extraction drugs that depend on flow. Third, hypoalbuminemia increases the free fraction of protein-bound drugs, enhancing pharmacological action and distribution. Fourth, cholestasis can reduce biliary excretion of drugs and metabolites. Clinicians use Child-Pugh or MELD scores to quantify the severity of liver dysfunction and follow regulatory guidelines (e.g., FDA) that recommend dose reductions based on these scores. For drugs with a narrow therapeutic index, such as warfarin, opioids, and some antiepileptics, dose adjustment and therapeutic drug monitoring are critical. This principle ensures that patients with hepatic impairment receive effective but safe doses.